

New Assay and Panel: Hepatitis B Virus Core Antibody, IgM and Hepatitis Panel, Acute

Date: April 8th, 2022

Effective Date: May 4th, 2022

UR Medicine Labs will offer a new FDA-approved serologic test for the qualitative detection of IgM class antibody to Hepatitis B Virus core antigen (IgM anti-HBc). Test results will be reported as Non-reactive, Equivocal, or Reactive. The detection of IgM anti-HBc may be regarded as a marker for acute Hepatitis B Virus infection, particularly for patients who may be in the window period when Hepatitis B Surface Antigen (HBsAg) declines and before Hepatitis B Virus Surface IgG Antibody (anti-HBs) appears.

Test name: Hepatitis B Virus Core Antibody, IgM.

Test code: HBCM

Method: chemiluminescent micro particle immunoassay (CMIA).

Sample type: 1.0 mL serum, serum separator tube (SST).

Turn-around-time: 1-2 days.

The Hepatitis B Virus Core Antibody, IgM test will be orderable stand-alone, or as a component of a new panel.

Panel name: Hepatitis Panel, Acute

Test code: AHEP

The panel includes the following serologic tests:

- Hepatitis A Virus, IgM.
- Hepatitis B Virus Surface Antigen with reflex to HBsAg Confirmation.
- Hepatitis B Virus Core Antibody, IgM.
- Hepatitis C Virus Antibody with reflex to Hepatitis C Virus RNA Quant, Real Time PCR.

For questions or additional information, please contact Lindsay Ryan (Serology supervisor) Lindsay_Ryan-muntz@URMC.Rochester.edu or Andrew Cameron, PhD.

From: Andrew Cameron, PhD D(ABMM)

Assistant Director, Clinical Microbiology, UR Medicine Labs

University of Rochester Medical Center

Phone: (585) 276-4674

E-mail: andrew_cameron@urmc.rochester.edu